{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T14:32:08Z","timestamp":1760711528476,"version":"build-2065373602"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s00520-025-09543-1","type":"journal-article","created":{"date-parts":[[2025,5,18]],"date-time":"2025-05-18T21:01:21Z","timestamp":1747602081000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Standardized gynecologic consultation and bone surveillance in patients with breast cancer receiving hormone therapy"],"prefix":"10.1007","volume":"33","author":[{"given":"Ching-Wen","family":"Chiu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Ming","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Min","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun-Ting","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsueh-Chi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ka-Wai","family":"Tam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"key":"9543_CR1","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1806","volume":"6","author":"M Ghanavati","year":"2023","unstructured":"Ghanavati M, Khorshidi Y, Shadnoush M et al (2023) Tamoxifen use and risk of endometrial cancer in breast cancer patients: a systematic review and dose-response meta-analysis. Cancer Rep (Hoboken) 6:e1806. https:\/\/doi.org\/10.1002\/cnr2.1806","journal-title":"Cancer Rep (Hoboken)"},{"key":"9543_CR2","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1016\/S0140-6736(13)60140-3","volume":"381","author":"J Cuzick","year":"2013","unstructured":"Cuzick J, Sestak I, Bonanni B et al (2013) Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet 381:1827\u20131834. https:\/\/doi.org\/10.1016\/S0140-6736(13)60140-3","journal-title":"Lancet"},{"key":"9543_CR3","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s11864-024-01190-8","volume":"25","author":"C Molinelli","year":"2024","unstructured":"Molinelli C, Jacobs F, Nader-Marta G et al (2024) Ovarian suppression: early menopause and late effects. Curr Treat Opt Oncol 25:523\u2013542. https:\/\/doi.org\/10.1007\/s11864-024-01190-8","journal-title":"Curr Treat Opt Oncol"},{"key":"9543_CR4","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1200\/JCO.1999.17.9.2659","volume":"17","author":"R Day","year":"1999","unstructured":"Day R, Ganz PA, Costantino JP, Cronin WM, Wickerham DL, Fisher B (1999) Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Clin Oncol 17:2659\u20132669. https:\/\/doi.org\/10.1200\/JCO.1999.17.9.2659","journal-title":"J Clin Oncol"},{"key":"9543_CR5","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1634\/theoncologist.2015-0007","volume":"20","author":"SM Rosenberg","year":"2015","unstructured":"Rosenberg SM, Stanton AL, Petrie KJ, Partridge AH (2015) Symptoms and symptom attribution among women on endocrine therapy for breast cancer. Oncologist 20:598\u2013604. https:\/\/doi.org\/10.1634\/theoncologist.2015-0007","journal-title":"Oncologist"},{"key":"9543_CR6","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1093\/jnci\/91.19.1654","volume":"91","author":"L Bernstein","year":"1999","unstructured":"Bernstein L, Deapen D, Cerhan JR et al (1999) Tamoxifen therapy for breast cancer and endometrial cancer risk. J Natl Cancer Inst 91:1654\u20131662. https:\/\/doi.org\/10.1093\/jnci\/91.19.1654","journal-title":"J Natl Cancer Inst"},{"key":"9543_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.636378","volume":"11","author":"S Choi","year":"2021","unstructured":"Choi S, Lee YJ, Jeong JH et al (2021) Risk of endometrial cancer and frequencies of invasive endometrial procedures in young breast cancer survivors treated with tamoxifen: a nationwide study. Front Oncol 11:636378. https:\/\/doi.org\/10.3389\/fonc.2021.636378","journal-title":"Front Oncol"},{"key":"9543_CR8","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1200\/JCO.2005.09.121","volume":"23","author":"EP Winer","year":"2005","unstructured":"Winer EP, Hudis C, Burstein HJ et al (2005) American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 23:619\u2013629. https:\/\/doi.org\/10.1200\/JCO.2005.09.121","journal-title":"J Clin Oncol"},{"key":"9543_CR9","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.critrevonc.2008.07.013","volume":"69","author":"P Hadji","year":"2009","unstructured":"Hadji P (2009) Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis. Crit Rev Oncol Hematol 69:73\u201382. https:\/\/doi.org\/10.1016\/j.critrevonc.2008.07.013","journal-title":"Crit Rev Oncol Hematol"},{"key":"9543_CR10","unstructured":"Perez EA, Weilbaecher K (2006) Aromatase inhibitors and bone loss. Oncology (Williston Park) 20:1029\u20131039. discussion 1039\u201340, 1042, 1048"},{"key":"9543_CR11","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1152\/physrev.00033.2015","volume":"97","author":"M Almeida","year":"2017","unstructured":"Almeida M, Laurent MR, Dubois V et al (2017) Estrogens and androgens in skeletal physiology and pathophysiology. Physiol Rev 97:135\u2013187. https:\/\/doi.org\/10.1152\/physrev.00033.2015","journal-title":"Physiol Rev"},{"key":"9543_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jbo.2017.03.001","volume":"7","author":"P Hadji","year":"2017","unstructured":"Hadji P, Aapro MS, Body JJ et al (2017) Management of aromatase inhibitor-associated bone loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG. J Bone Oncol 7:1\u201312. https:\/\/doi.org\/10.1016\/j.jbo.2017.03.001","journal-title":"J Bone Oncol"},{"key":"9543_CR13","unstructured":"National Comprehensive Cancer Network (2025) NCCN Clinical Practice Guidelines in Oncology, breast cancer, version 4.2025"},{"key":"9543_CR14","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1136\/bmjqs-2013-001862","volume":"23","author":"MJ Taylor","year":"2014","unstructured":"Taylor MJ, McNicholas C, Nicolay C, Darzi A, Bell D, Reed JE (2014) Systematic review of the application of the plan-do-study-act method to improve quality in healthcare. BMJ Qual Saf 23:290\u2013298. https:\/\/doi.org\/10.1136\/bmjqs-2013-001862","journal-title":"BMJ Qual Saf"},{"key":"9543_CR15","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1188\/22.CJON.483-486","volume":"26","author":"M Patel","year":"2022","unstructured":"Patel M, Leak Bryant A, Mayer DK, Winzelberg G (2022) Using the PDSA framework to improve rates of clinical tool use in outpatient oncology palliative care clinics. Clin J Oncol Nurs 26:483\u2013486. https:\/\/doi.org\/10.1188\/22.CJON.483-486","journal-title":"Clin J Oncol Nurs"},{"key":"9543_CR16","unstructured":"SQUIRE: SQUIRE 2.0 guidelines. https:\/\/squire-statement.org\/index.cfm?fuseaction=Page.ViewPage&PageID=471.\u00a0Accessed April 2025"},{"key":"9543_CR17","doi-asserted-by":"crossref","unstructured":"ACOG-Committee Opinion (1996) Tamoxifen and endometrial cancer. Number 169, February 1996. Committee on gynecologicpractice. American College of Obstetrics and Gynecologists. Int J Gynecol Obstet 53:197\u2013199","DOI":"10.1016\/S0020-7292(96)90115-0"},{"key":"9543_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102624","volume":"120","author":"L Cucciniello","year":"2023","unstructured":"Cucciniello L, Garufi G, Di Rienzo R et al (2023) Estrogen deprivation effects of endocrine therapy in breast cancer patients: incidence, management and outcome. Cancer Treat Rev 120:102624. https:\/\/doi.org\/10.1016\/j.ctrv.2023.102624","journal-title":"Cancer Treat Rev"},{"key":"9543_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2024.103754","volume":"76","author":"L Cucciniello","year":"2024","unstructured":"Cucciniello L, Miglietta F, Guarneri V, Puglisi F (2024) Managing sexual health challenges in breast cancer survivors: a comprehensive review. Breast 76:103754. https:\/\/doi.org\/10.1016\/j.breast.2024.103754","journal-title":"Breast"},{"key":"9543_CR20","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1080\/14740338.2022.2151584","volume":"21","author":"P Di Nardo","year":"2022","unstructured":"Di Nardo P, Lisanti C, Garutti M et al (2022) Chemotherapy in patients with early breast cancer: clinical overview and management of long-term side effects. Expert Opin Drug Saf 21:1341\u20131355. https:\/\/doi.org\/10.1080\/14740338.2022.2151584","journal-title":"Expert Opin Drug Saf"},{"key":"9543_CR21","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S2213-8587(18)30047-0","volume":"6","author":"TD Rachner","year":"2018","unstructured":"Rachner TD, Coleman R, Hadji P, Hofbauer LC (2018) Bone health during endocrine therapy for cancer. Lancet Diabetes Endocrinol 6:901\u2013910. https:\/\/doi.org\/10.1016\/S2213-8587(18)30047-0","journal-title":"Lancet Diabetes Endocrinol"},{"key":"9543_CR22","doi-asserted-by":"publisher","first-page":"4042","DOI":"10.1200\/JCO.2003.08.017","volume":"21","author":"BE Hillner","year":"2003","unstructured":"Hillner BE, Ingle JN, Chlebowski RT (2003) American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21:4042\u20134057. https:\/\/doi.org\/10.1200\/JCO.2003.08.017","journal-title":"J Clin Oncol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09543-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-025-09543-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09543-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T09:12:07Z","timestamp":1759396327000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-025-09543-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["9543"],"URL":"https:\/\/doi.org\/10.1007\/s00520-025-09543-1","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"type":"print","value":"0941-4355"},{"type":"electronic","value":"1433-7339"}],"subject":[],"published":{"date-parts":[[2025,5,19]]},"assertion":[{"value":"12 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Joint Institutional Review Board of Taipei Medical University (approval no. N202306025). The procedures used in this study adhere to the tenets of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"479"}}